Clinical Trial Update: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial evaluating Lebrikizumab in children aged 6 months to under 18 years with moderate-to-severe atopic dermatitis; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis, Eczema | Phase 3 | Status: ACTIVE_NOT_RECRUITING